Europe Lentiviral Vector Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Published Report
  • Jun 2021
  • Europe
  • 350 Pages
  • No of Tables: 197
  • No of Figures: 52

Europe Lentiviral Vector Market, By Component (Lentiviral promoter, Lentiviral fusion tags, Lentivirus packaging systems and Other), Type (Product and Services), Generation (4th-generation, 3rd-generation, 2nd-generation and 1st-generation), Workflow (Upstream Processing And Downstream Processing), Delivery Method (In Vivo and Ex Vivo), Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease And Other), Application (Gene Therapy And Vaccinology), End User (Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO) and Academic/Research Institutes), Country (Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Rest Of Europe) Industry Trends and Forecast To 2028

Europe Lentiviral Vector Market

Market Analysis and Insights: Europe Lentiviral Vector Market

Europe lentiviral vector market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.9% in the forecast period of 2021 to 2028 and is expected to reach USD 322.41 million by 2028. Molecular biologists frequently use viral vectors to deliver genetic material into cells. This procedure can be carried out in vivo (inside a living organism) or in cell culture (in vitro). Viruses have developed specialized molecular mechanisms to transport their genomes efficiently inside the cells they infect. Growing demand for lentiviral vector and rise in infectious disease; are the major drivers which propelled the demand of the market in the forecast period.

Lentiviral vectors (LV) are efficient vehicles for gene transfer in mammalian cells due to their capacity to stably express a gene of interest in non-dividing and dividing cells. Lentiviruses are human and animal pathogens that are known to have long incubation periods and persistent infection. The time between the initial infection and the appearance of the first symptoms can reach several months or years. Molecular biologists frequently use viral vectors to deliver genetic material into cells. The procedure can be carried out in vivo (inside a living organism) or in cell culture (in vitro). Viruses have developed specialized molecular mechanisms to transport their genomes efficiently inside the cells they infect. Transduction is the delivery of genes or other genetic material by a vector and infected cells are referred to as transduced. Lentivirus vectors are also used in gene therapy and vaccine development, in addition to molecular biology research. Various products and services are obtainable by the key market players for the production of lentiviral vector.

Growing geriatric population and demand for vaccine developments during this Covid-19 emergence effectively help the growth of the lentiviral vector market. However, the lack of scalability and limitations of downstream purification of lentiviral vectors may hamper the future growth of a lentiviral vector market. The strategic initiatives by major market players and rise in funding for genomics act as opportunity for the growth of Europe lentiviral vector market. The stringent regulatory policies and side effects associated with lentiviral vector products act as challenge for future market growth.

The Europe lentiviral vector market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Lentiviral Vector Market

Europe Lentiviral Vector Market  Scope and Market Size

Europe lentiviral vector market is segmented into eight notable segments on the basis of the component, type, generation, workflow, delivery method, disease indication, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of component, the Europe lentiviral vector market is segmented into lentiviral promoter, lentiviral fusion tags, and lentivirus packaging systems and other. In 2021, lentivirus packaging system segment is expected to dominate the lentiviral vector market due to rising technological advancements.
  • On the basis of type, the Europe lentiviral vector market is segmented into product and services. In 2021, product segment is expected to dominate the lentiviral vector market due to rising investments for gene therapy by European government.
  • On the basis of generation, the Europe lentiviral vector market is segmented into 4th-generation, 3rd-generation, 2nd-generation and 1st-generation. In 2021, 4th generation segment is expected to dominate the lentiviral vector market due to its reduced mutagenesis and associated side effects.
  • On the basis of workflow, the Europe lentiviral vector market is segmented into upstream processing and downstream processing. In 2021, upstream processing segment is expected to dominate the lentiviral vector market due to rising research organizations and activities in gene therapy.
  • On the basis of delivery method, the Europe lentiviral vector market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the lentiviral vector market due to its accelerating research contributions and vaccine productions.
  • On the basis of disease indication, the Europe lentiviral vector market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, cancer segment is expected to dominate the lentiviral vector market owing to the rising incidence of cancer cases in various regions of Europe.
  • On the basis of application, the Europe lentiviral vector market is segmented into gene therapy and vaccinology. In 2021, gene therapy segment is expected to dominate the lentiviral vector market due to broad range of its application and permanent cure provided for chronic diseases.
  • On the basis of end user, the Europe lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to increasing number of new research institutes launches for R & D applications.

Europe Lentiviral Vector Market Country Level Analysis

The Europe lentiviral vector market is analysed and market size information is provided by component, type, generation, workflow, delivery method, disease indication, application and end user.

The countries covered in the Europe lentiviral vector market report are the U.K, Germany, France, Italy, Spain, Russia, Turkey, Netherlands, Switzerland and rest of Europe.    

Germany is the fastest growing and hence, the dominating country in the Europe region due to rising pharmaceutical industries initiatives for the lentiviral vector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Increasing Strategic Initiatives by Key Market Players for Lentiviral Vector Production is Creating New Opportunities in the Lentiviral Vector Market    

Europe Lentiviral Vector market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.

Competitive Landscape and Europe Lentiviral Vector Market Share Analysis

Europe lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to lentiviral vector market.

The major companies which are dealing in the Europe lentiviral vector market are Applied Biological Materials Inc., Creative Biolabs, bluebird bio, Inc., System Biosciences, LLC, Cobra Biologics Limited, FUJIFILM Diosynth Biotechnologies (a subsidiary of FUJIFILM Holdings Corporation), Sirion-Biotech GmbH, Merck KGaA, FinVector Oy, Oxford Biomedica, OriGene Technologies, Inc., Sino Biological Inc., Batavia Biosciences B.V., Lonza, Takara Bio Inc., Thermo Fisher Scientific Inc., and Cytiva (a subsidiary of Danaher) among others.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the lentiviral vector market.

For instance,

  • In September 2020, Waisman Biomanufacturing underwent strategic partnership with the California-based biotech company GigaGen in order to develop a new drug to treat and prevent COVID-19. This strategic partnership done by the company will increase the use of development and testing of new types of drugs by the Waisman Biomanufacturing leading to increased awareness of its services in the market.
  • In April 2021, Oxford Biomedica signs a new three-year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors. It is predicted that this agreement anticipated enhancing the sales growth of the company in the coming years.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the lentiviral vector market which also provides the benefit for organization’s profit growth.

Customization Available: Europe Lentiviral Vector Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 THERMO FISHER SCIENTIFIC

TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN

TABLE 3 KERAFAST

TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.

TABLE 5 EUROPE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 6 EUROPE LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 EUROPE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 EUROPE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 9 EUROPE LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 EUROPE OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 EUROPE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 EUROPE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 EUROPE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 EUROPE SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 EUROPE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 16 EUROPE 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 EUROPE 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 EUROPE 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 EUROPE 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 EUROPE LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)

TABLE 21 EUROPE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 EUROPE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 23 EUROPE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 EUROPE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 25 EUROPE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 26 EUROPE IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 EUROPE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 EUROPE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 32 EUROPE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 EUROPE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 34 EUROPE VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 EUROPE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 37 EUROPE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 EUROPE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 EUROPE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 41 EUROPE ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 EUROPE PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 EUROPE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 EUROPE BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 EUROPE LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 EUROPE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 48 EUROPE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 49 EUROPE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 EUROPE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 EUROPE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 52 EUROPE LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 53 EUROPE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 54 EUROPE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 55 EUROPE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 56 EUROPE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 57 EUROPE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 58 EUROPE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 59 EUROPE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 EUROPE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 61 EUROPE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 U.K. LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 63 U.K. LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 64 U.K. LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 U.K. PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 U.K. LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 67 U.K. LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 68 U.K. UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 69 U.K. DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 70 U.K. LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 71 U.K. LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 72 U.K. GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 73 U.K. INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 74 U.K. LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 75 U.K. GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 76 U.K. LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 77 GERMANY LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 78 GERMANY LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 79 GERMANY LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 GERMANY PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 GERMANY LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 82 GERMANY LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 83 GERMANY UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 84 GERMANY DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 85 GERMANY LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 86 GERMANY LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 87 GERMANY GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 88 GERMANY INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 89 GERMANY LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 90 GERMANY GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 91 GERMANY LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 FRANCE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 93 FRANCE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 94 FRANCE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 FRANCE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 96 FRANCE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 97 FRANCE LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 98 FRANCE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 99 FRANCE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 100 FRANCE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 101 FRANCE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 102 FRANCE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 103 FRANCE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 104 FRANCE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 105 FRANCE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 FRANCE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 ITALY LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 108 ITALY LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 109 ITALY LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 ITALY PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 ITALY LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 112 ITALY LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 113 ITALY UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 114 ITALY DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 115 ITALY LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 116 ITALY LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 117 ITALY GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 118 ITALY INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 119 ITALY LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 120 ITALY GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 121 ITALY LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 122 SPAIN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 123 SPAIN LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 124 SPAIN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 125 SPAIN PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 126 SPAIN LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 127 SPAIN LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 128 SPAIN UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 129 SPAIN DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 130 SPAIN LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 131 SPAIN LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 132 SPAIN GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 133 SPAIN INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 134 SPAIN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 135 SPAIN GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 136 SPAIN LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 138 NETHERLANDS LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 139 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 NETHERLANDS PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 141 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 142 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 143 NETHERLANDS UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 144 NETHERLANDS DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 145 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 146 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 147 NETHERLANDS GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 148 NETHERLANDS INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 149 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 150 NETHERLANDS GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 NETHERLANDS LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 152 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 153 SWITZERLAND LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 154 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 SWITZERLAND PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 157 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 158 SWITZERLAND UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 159 SWITZERLAND DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 160 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 161 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 162 SWITZERLAND GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 163 SWITZERLAND INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 164 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 165 SWITZERLAND GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 166 SWITZERLAND LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 167 RUSSIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 168 RUSSIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 169 RUSSIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 170 RUSSIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 171 RUSSIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 172 RUSSIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 173 RUSSIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 174 RUSSIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 175 RUSSIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 176 RUSSIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 177 RUSSIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 178 RUSSIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 179 RUSSIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 180 RUSSIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 181 RUSSIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 182 TURKEY LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 183 TURKEY LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 184 TURKEY LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 185 TURKEY PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 186 TURKEY LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 187 TURKEY LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 188 TURKEY UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 189 TURKEY DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 190 TURKEY LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 191 TURKEY LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 192 TURKEY GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 193 TURKEY INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 194 TURKEY LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 195 TURKEY GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 196 TURKEY LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 197 REST OF EUROPE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions